Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
Adaptimmune was founded in 2008 by Ian Laing, James Noble.
1282 health care and life sciences companies are in the directory, 61 of them in the same 501-1,000 employee range and 131 based in Europe.
Adaptimmune may be growing as evidenced by the significant appreciation in its stock value, with reports indicating an impressive 58% increase this month. Analysts have also made notable upgrades to their forecasts for the company, which suggests a positive outlook on the company's financial performance. Despite the discontinuation of certain programs, the overall sentiment from shareholders appears to be positive, as indicated by reasons to smile mentioned in the news articles.
“Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients” adaptimmune.com
Adaptimmune is a biopharma company based in Europe, with 501-1,000 employees, founded in 2008. Its founders are Ian Laing and James Noble and it has raised $499.5 million over 9 rounds.
101-250 employees · adicetbio.com
501-1,000 employees · apcerls.com
1,001-5,000 employees · aconlabs.com
251-500 employees · accelgen.com
1-10 employees · 101therapeutics.com
101-250 employees · aveooncology.com
11-50 employees · adslaboratories.com
51-100 employees · abingdonhealth.com
1-10 employees · 20visioneers15.com
11-50 employees · airna.com
Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.